Propanc Biopharma, Inc. (PPCB)

$0.0024

-0.00 (-5.88%)
Rating:
Recommendation:
-
Symbol PPCB
Price $0.0024
Beta 1.631
Volume Avg. 19.78M
Market Cap 0.293M
Shares () -
52 Week Range 0.0018-0.05
1y Target Est -
DCF Unlevered PPCB DCF ->
DCF Levered PPCB LDCF ->
ROE 90.02% Strong Buy
ROA -1494.36% Strong Sell
Operating Margin -
Debt / Equity -105.75% Sell
P/E -
P/B -0.05 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. James Nathanielsz
Healthcare
Biotechnology
Other OTC

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.